Literature DB >> 25766095

Restoration of mitochondria function as a target for cancer therapy.

Tariq A Bhat1, Sandeep Kumar1, Ajay K Chaudhary1, Neelu Yadav1, Dhyan Chandra2.   

Abstract

Defective oxidative phosphorylation has a crucial role in the attenuation of mitochondrial function, which confers therapy resistance in cancer. Various factors, including endogenous heat shock proteins (HSPs) and exogenous agents such as dichloroacetate, restore respiratory and other physiological functions of mitochondria in cancer cells. Functional mitochondria might ultimately lead to the restoration of apoptosis in cancer cells that are refractory to current anticancer agents. Here, we summarize the key reasons contributing to mitochondria dysfunction in cancer cells and how restoration of mitochondrial function could be exploited for cancer therapeutics.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25766095      PMCID： PMC4433775          DOI： 10.1016/j.drudis.2015.03.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  121 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 3.  Mitochondria: gatekeepers of response to chemotherapy.

Authors:  Kristopher A Sarosiek; Triona Ni Chonghaile; Anthony Letai
Journal:  Trends Cell Biol       Date:  2013-09-21       Impact factor: 20.808

Review 4.  Defects of the apoptotic pathway as therapeutic target against cancer.

Authors:  Tetsuo Mashima; Takashi Tsuruo
Journal:  Drug Resist Updat       Date:  2005-12-09       Impact factor: 18.500

5.  Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.

Authors:  Jing Xie; Bing-Shun Wang; De-Hong Yu; Qin Lu; Jian Ma; Hong Qi; Chao Fang; Hong-Zhuan Chen
Journal:  Int J Oncol       Date:  2010-12-03       Impact factor: 5.650

6.  Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.

Authors:  Duyen T Dang; Fang Chen; Lawrence B Gardner; Jordan M Cummins; Carlo Rago; Fred Bunz; Sergey V Kantsevoy; Long H Dang
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

7.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 8.  Mitochondrial DNA mutations and breast tumorigenesis.

Authors:  Neelu Yadav; Dhyan Chandra
Journal:  Biochim Biophys Acta       Date:  2013-10-16

9.  Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism.

Authors:  Jian Chen; Songji Zhao; Kunihiro Nakada; Yuji Kuge; Nagara Tamaki; Futoshi Okada; Jingxin Wang; Masanobu Shindo; Fumihiro Higashino; Kohji Takeda; Masahiro Asaka; Hiroyuki Katoh; Toshio Sugiyama; Masuo Hosokawa; Masanobu Kobayashi
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

10.  Surveillance-activated defenses block the ROS-induced mitochondrial unfolded protein response.

Authors:  Eva D Runkel; Shu Liu; Ralf Baumeister; Ekkehard Schulze
Journal:  PLoS Genet       Date:  2013-03-14       Impact factor: 5.917
View more
  28 in total

1.  The Mitochondria-Targeted Plastoquinone-Derivative SkQ1 Promotes Health and Increases Drosophila melanogaster Longevity in Various Environments.

Authors:  Eugenia Tsybul'ko; Anna Krementsova; Alexander Symonenko; Olga Rybina; Natalia Roshina; Elena Pasyukova
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-04-01       Impact factor: 6.053

2.  Studies on Photocleavage, DNA Binding, Cytotoxicity, and Docking Studies of Ruthenium(II) Mixed Ligand Complexes.

Authors:  Yata Praveen Kumar; C Shobha Devi; A Srishailam; N Deepika; V Ravi Kumar; P Venkat Reddy; K Nagasuryaprasad; Surya S Singh; Penumaka Nagababu; S Satyanarayana
Journal:  J Fluoresc       Date:  2016-09-02       Impact factor: 2.217

3.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors:  Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 4.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

Review 5.  VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation.

Authors:  Diana Fang; Eduardo N Maldonado
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

6.  KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.

Authors:  Ling-Yu Wang; Chiu-Lien Hung; Yun-Ru Chen; Joy C Yang; Junjian Wang; Mel Campbell; Yoshihiro Izumiya; Hong-Wu Chen; Wen-Ching Wang; David K Ann; Hsing-Jien Kung
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

7.  JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells.

Authors:  K A Heslop; A Rovini; E G Hunt; D Fang; M E Morris; C F Christie; M B Gooz; D N DeHart; Y Dang; J J Lemasters; E N Maldonado
Journal:  Biochem Pharmacol       Date:  2019-11-21       Impact factor: 5.858

8.  Interaction of Age at Diagnosis with Transcriptional Profiling in Papillary Thyroid Cancer.

Authors:  Yi-Chiung Hsu; Chien-Liang Liu; Po-Sheng Yang; Chung-Hsin Tsai; Jie-Jen Lee; Shih-Ping Cheng
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

9.  IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α-regulated pseudohypoxic state.

Authors:  Yuan Wang; Ekta Agarwal; Irene Bertolini; Jagadish C Ghosh; Jae Ho Seo; Dario C Altieri
Journal:  FASEB J       Date:  2019-09-17       Impact factor: 5.834

10.  Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism.

Authors:  Liang-Dong Li; He-Fen Sun; Xue-Xiao Liu; Shui-Ping Gao; Hong-Lin Jiang; Xin Hu; Wei Jin
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.